| NCT07211633 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | RECRUITING | PHASE3 | 2025-07-09 | 2028-12-31 | 2026-12-31 |
| NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | RECRUITING | PHASE1 | 2025-05-06 | 2029-01-01 | 2026-12-01 |
| NCT05877963 | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | RECRUITING | PHASE3 | 2023-06-13 | 2026-03-01 | 2026-03-01 |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | TERMINATED | PHASE1 | 2021-04-28 | 2024-06-12 | 2024-06-12 |
| NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-11-18 | 2030-02-01 | 2030-02-01 |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | TERMINATED | PHASE2 | 2019-08-05 | 2022-05-22 | 2022-05-22 |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | TERMINATED | PHASE2 | 2019-07-10 | 2022-05-31 | 2022-05-16 |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | TERMINATED | PHASE2, PHASE3 | 2019-05-16 | 2022-12-20 | 2022-12-20 |
| NCT03778073 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | TERMINATED | PHASE1 | 2019-04-17 | 2022-08-01 | 2022-05-03 |
| NCT03804996 | Study of TG-1801 in Subjects With B-Cell Lymphoma | COMPLETED | PHASE1 | 2019-03-05 | 2024-02-21 | 2024-02-21 |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | TERMINATED | PHASE1 | 2018-09-10 | 2024-05-21 | 2024-05-21 |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | TERMINATED | PHASE1, PHASE2 | 2018-03-27 | 2022-06-16 | 2022-05-26 |
| NCT03364231 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | COMPLETED | PHASE2 | 2017-11-30 | 2022-02-15 | 2022-02-15 |
| NCT03277261 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) | COMPLETED | PHASE3 | 2017-09-19 | 2020-11-06 | 2020-07-23 |
| NCT03277248 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) | COMPLETED | PHASE3 | 2017-08-25 | 2020-11-12 | 2020-08-04 |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | TERMINATED | PHASE2 | 2017-08-09 | 2022-06-24 | 2022-05-25 |
| NCT03381170 | An Extension of the TG1101-RMS201 Trial | COMPLETED | PHASE2 | 2017-06-01 | 2022-11-11 | 2022-11-11 |
| NCT02738775 | Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis | COMPLETED | PHASE2 | 2016-05-27 | 2018-08-13 | 2017-09-27 |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | TERMINATED | PHASE2, PHASE3 | 2016-05-25 | 2022-07-04 | 2022-05-31 |
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | TERMINATED | PHASE2 | 2016-04-21 | 2021-06-10 | 2021-06-10 |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | TERMINATED | PHASE2 | 2016-01-07 | 2022-07-11 | 2022-05-26 |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | TERMINATED | PHASE3 | 2015-11-19 | 2023-02-22 | 2023-02-22 |
| NCT02535286 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | COMPLETED | PHASE1 | 2015-09-18 | 2021-11-04 | 2021-11-04 |
| NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | COMPLETED | PHASE1 | 2015-09-11 | 2018-08 | 2018-08 |
| NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE3 | 2015-01-27 | 2020-04-01 | 2020-04-01 |
| NCT02164006 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients | COMPLETED | PHASE1 | 2014-06-11 | 2016-05 | 2016-05 |
| NCT02100852 | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE1 | 2014-03-12 | 2017-11 | 2017-11 |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | COMPLETED | PHASE1, PHASE2 | 2014-01-06 | 2015-12 | 2015-12 |
| NCT02006485 | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | COMPLETED | PHASE1 | 2013-12-13 | 2019-10 | 2019-10 |
| NCT01767766 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | COMPLETED | PHASE1 | 2013-01-07 | 2018-02 | 2018-02 |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | TERMINATED | PHASE1 | 2012-11-21 | 2014-02-07 | 2014-02-07 |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | COMPLETED | PHASE1, PHASE2 | 2012-07-19 | 2015-05 | 2015-05 |